Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study

J. Bousquet; S. Arnavielhe; A. Bedbrook; G. Alexis-Alexandre; M. van Eerd; R. Murray; G. W. Canonica; M. Illario; E. Menditto; G. Passalacqua; C. Stellato; M. Triggiani; P. Carreiro-Martins; J. Fonseca; M. Morais Almeida; L. Nogueira-Silva; A. M. Pereira; A. Todo Bom; I. Bosse; D. Caimmi; P. Demoly; P. Devillier; J. F. Fontaine; J. Just; G. L. Onorato; M. L. Kowalski; P. Kuna; B. Samolinski; J. M. Anto; J. Mullol; A. Valero; P. V. Tomazic; K. C. Bergmann; T. Keil; L. Klimek; R. Mösgues; S. Shamai; T. Zuberbier; E. Murphy; Peter McDowall; D. Price; D. Ryan; A. Sheikh; N. H. Chavannes; W. J. Fokkens; V. Kvedariene; A. Valiulis; C. Bachert; P. W. Hellings; I. Kull; E. Melén; M. Wickman; C. Bindslev-Jensen; E. Eller; T. Haahtela; E. Valovirta; N. G. Papadopoulos; I. Annesi-Maesano; M. Bewick; S. Bosnic-Anticevich; A. A. Cruz; G. de Vries; B. Gemicioglu; D. Larenas-Linnemann; D. Laune; E. Mathieu-Dupas; R. E. O'Hehir; F. Portejoie; V. Siroux; O. Spranger; O. Vandenplas; A. Yorgancioglu

doi:https://doi.org/10.1111/all.13406

Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study

J. Bousquet, S. Arnavielhe, A. Bedbrook, G. Alexis-Alexandre, M. van Eerd, R. Murray, G. W. Canonica, M. Illario, E. Menditto, G. Passalacqua, C. Stellato, M. Triggiani, P. Carreiro-Martins, J. Fonseca, M. Morais Almeida, L. Nogueira-Silva, A. M. Pereira, A. Todo Bom, I. Bosse, D. CaimmiP. Demoly, P. Devillier, J. F. Fontaine, J. Just, G. L. Onorato, M. L. Kowalski, P. Kuna, B. Samolinski, J. M. Anto, J. Mullol, A. Valero, P. V. Tomazic, K. C. Bergmann, T. Keil, L. Klimek, R. Mösgues, S. Shamai, T. Zuberbier, E. Murphy, Peter McDowall, D. Price, D. Ryan, A. Sheikh, N. H. Chavannes, W. J. Fokkens, V. Kvedariene, A. Valiulis, C. Bachert, P. W. Hellings, I. Kull, E. Melén, M. Wickman, C. Bindslev-Jensen, E. Eller, T. Haahtela, E. Valovirta, N. G. Papadopoulos, I. Annesi-Maesano, M. Bewick, S. Bosnic-Anticevich, A. A. Cruz, G. de Vries, B. Gemicioglu, D. Larenas-Linnemann, D. Laune, E. Mathieu-Dupas, R. E. O'Hehir, F. Portejoie, V. Siroux, O. Spranger, O. Vandenplas, A. Yorgancioglu

Research output: Contribution to journal › Article › Academic › peer-review

103 Citations (Scopus)

Abstract

Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology. A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control). The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved

Original language	English
Pages (from-to)	1763-1774
Journal	Allergy
Volume	73
Issue number	9
DOIs	https://doi.org/10.1111/all.13406
Publication status	Published - 2018

Access to Document

https://doi.org/10.1111/all.13406

Cite this

Bousquet, J., Arnavielhe, S., Bedbrook, A., Alexis-Alexandre, G., van Eerd, M., Murray, R., Canonica, G. W., Illario, M., Menditto, E., Passalacqua, G., Stellato, C., Triggiani, M., Carreiro-Martins, P., Fonseca, J., Morais Almeida, M., Nogueira-Silva, L., Pereira, A. M., Todo Bom, A., Bosse, I., ... Yorgancioglu, A. (2018). Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study. Allergy, 73(9), 1763-1774. https://doi.org/10.1111/all.13406

@article{b739492cf3c04dae8b72f3ed137e0adb,

title = "Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study",

abstract = "Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect {"}real world{"} everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology. A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control). The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved",

author = "J. Bousquet and S. Arnavielhe and A. Bedbrook and G. Alexis-Alexandre and {van Eerd}, M. and R. Murray and Canonica, {G. W.} and M. Illario and E. Menditto and G. Passalacqua and C. Stellato and M. Triggiani and P. Carreiro-Martins and J. Fonseca and {Morais Almeida}, M. and L. Nogueira-Silva and Pereira, {A. M.} and {Todo Bom}, A. and I. Bosse and D. Caimmi and P. Demoly and P. Devillier and Fontaine, {J. F.} and J. Just and Onorato, {G. L.} and Kowalski, {M. L.} and P. Kuna and B. Samolinski and Anto, {J. M.} and J. Mullol and A. Valero and Tomazic, {P. V.} and Bergmann, {K. C.} and T. Keil and L. Klimek and R. M{\"o}sgues and S. Shamai and T. Zuberbier and E. Murphy and Peter McDowall and D. Price and D. Ryan and A. Sheikh and Chavannes, {N. H.} and Fokkens, {W. J.} and V. Kvedariene and A. Valiulis and C. Bachert and Hellings, {P. W.} and I. Kull and E. Mel{\'e}n and M. Wickman and C. Bindslev-Jensen and E. Eller and T. Haahtela and E. Valovirta and Papadopoulos, {N. G.} and I. Annesi-Maesano and M. Bewick and S. Bosnic-Anticevich and Cruz, {A. A.} and {de Vries}, G. and B. Gemicioglu and D. Larenas-Linnemann and D. Laune and E. Mathieu-Dupas and O'Hehir, {R. E.} and F. Portejoie and V. Siroux and O. Spranger and O. Vandenplas and A. Yorgancioglu",

year = "2018",

doi = "https://doi.org/10.1111/all.13406",

language = "English",

volume = "73",

pages = "1763--1774",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "9",

}

Bousquet, J, Arnavielhe, S, Bedbrook, A, Alexis-Alexandre, G, van Eerd, M, Murray, R, Canonica, GW, Illario, M, Menditto, E, Passalacqua, G, Stellato, C, Triggiani, M, Carreiro-Martins, P, Fonseca, J, Morais Almeida, M, Nogueira-Silva, L, Pereira, AM, Todo Bom, A, Bosse, I, Caimmi, D, Demoly, P, Devillier, P, Fontaine, JF, Just, J, Onorato, GL, Kowalski, ML, Kuna, P, Samolinski, B, Anto, JM, Mullol, J, Valero, A, Tomazic, PV, Bergmann, KC, Keil, T, Klimek, L, Mösgues, R, Shamai, S, Zuberbier, T, Murphy, E, McDowall, P, Price, D, Ryan, D, Sheikh, A, Chavannes, NH, Fokkens, WJ, Kvedariene, V, Valiulis, A, Bachert, C, Hellings, PW, Kull, I, Melén, E, Wickman, M, Bindslev-Jensen, C, Eller, E, Haahtela, T, Valovirta, E, Papadopoulos, NG, Annesi-Maesano, I, Bewick, M, Bosnic-Anticevich, S, Cruz, AA, de Vries, G, Gemicioglu, B, Larenas-Linnemann, D, Laune, D, Mathieu-Dupas, E, O'Hehir, RE, Portejoie, F, Siroux, V, Spranger, O, Vandenplas, O & Yorgancioglu, A 2018, 'Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study', Allergy, vol. 73, no. 9, pp. 1763-1774. https://doi.org/10.1111/all.13406

TY - JOUR

T1 - Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study

AU - Bousquet, J.

AU - Arnavielhe, S.

AU - Bedbrook, A.

AU - Alexis-Alexandre, G.

AU - van Eerd, M.

AU - Murray, R.

AU - Canonica, G. W.

AU - Illario, M.

AU - Menditto, E.

AU - Passalacqua, G.

AU - Stellato, C.

AU - Triggiani, M.

AU - Carreiro-Martins, P.

AU - Fonseca, J.

AU - Morais Almeida, M.

AU - Nogueira-Silva, L.

AU - Pereira, A. M.

AU - Todo Bom, A.

AU - Bosse, I.

AU - Caimmi, D.

AU - Demoly, P.

AU - Devillier, P.

AU - Fontaine, J. F.

AU - Just, J.

AU - Onorato, G. L.

AU - Kowalski, M. L.

AU - Kuna, P.

AU - Samolinski, B.

AU - Anto, J. M.

AU - Mullol, J.

AU - Valero, A.

AU - Tomazic, P. V.

AU - Bergmann, K. C.

AU - Keil, T.

AU - Klimek, L.

AU - Mösgues, R.

AU - Shamai, S.

AU - Zuberbier, T.

AU - Murphy, E.

AU - McDowall, Peter

AU - Price, D.

AU - Ryan, D.

AU - Sheikh, A.

AU - Chavannes, N. H.

AU - Fokkens, W. J.

AU - Kvedariene, V.

AU - Valiulis, A.

AU - Bachert, C.

AU - Hellings, P. W.

AU - Kull, I.

AU - Melén, E.

AU - Wickman, M.

AU - Bindslev-Jensen, C.

AU - Eller, E.

AU - Haahtela, T.

AU - Valovirta, E.

AU - Papadopoulos, N. G.

AU - Annesi-Maesano, I.

AU - Bewick, M.

AU - Bosnic-Anticevich, S.

AU - Cruz, A. A.

AU - de Vries, G.

AU - Gemicioglu, B.

AU - Larenas-Linnemann, D.

AU - Laune, D.

AU - Mathieu-Dupas, E.

AU - O'Hehir, R. E.

AU - Portejoie, F.

AU - Siroux, V.

AU - Spranger, O.

AU - Vandenplas, O.

AU - Yorgancioglu, A.

PY - 2018

Y1 - 2018

N2 - Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology. A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control). The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved

AB - Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology. A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control). The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved

U2 - https://doi.org/10.1111/all.13406

DO - https://doi.org/10.1111/all.13406

M3 - Article

C2 - 29336067

SN - 0105-4538

VL - 73

SP - 1763

EP - 1774

JO - Allergy

JF - Allergy

IS - 9

ER -